Chronic Obstructive Pulmonary Disease - Heat Map and Analysis

Wednesday, March 8, 2017 Respiratory Disease News
Email Print This Page Comment
Font : A-A+

LONDON, March 7, 2017 /PRNewswire/ -- Chronic Obstructive  Pulmonary Disease - Heat Map and AnalysisSummaryChronic

Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of
morbidity, and the fifth-leading cause of death in the world.Download the full report: disease is characterized by structural changes that result in a narrowing of the small airways, ultimately causing airflow limitation. Both parenchymal destruction – termed emphysema – and small airways disease – referred to as chronic bronchitis – contribute towards these changes, which occur in varying degrees in each patient.Bronchodilators are established as the main classes of pharmacological maintenance treatment in COPD. They can be administered orally, intravenously or, if preferred, inhaled. The various forms of bronchodilators can be classed as short-acting or long-acting, and both are used in the management of COPD. Although bronchodilators play the key role in the management of COPD symptoms, other forms of treatment are also widely used. Inhaled corticosteroids (ICS) such as fluticasone propionate and budesonide are used to manage inflammation in both COPD and asthma patients. ICSs bind to the glucocorticoid receptors in the airways, reducing inflammation. In addition, there are signs of more innovative products emerging onto the treatment landscape. An example includes a monoclonal antibody – a class of therapy that has already emerged for asthma – that is in Phase III development.The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heatmap framework, designed to provide an easily digestible Summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the COPD market and late-stage pipeline. These are split along lines of therapy, and are therefore reflective of the treatment algorithm.All safety and efficacy endpoints reported in these trials are displayed, for both the drug and comparison groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.Scope- What are the clinical characteristics of currently approved therapies for COPD, in terms of specific safety and efficacy parameters?- What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are most closely linked to them?- Which novel classes of combination therapy are expected to emerge in the treatment of COPD?- Which first-in-class products are in development for COPD and what targets do they act upon?- Which sub-types of patients could potentially benefit from these new products?Reasons to buy- Understand the current clinical landscape by considering the treatment options available for each patient segment.- Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.- Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.- Understand the relative strengths and weaknesses of the studies used to gather these data.- Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.- Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.Download the full report: ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith Research Advisor at Email: Tel: +44 208 816 85 48 Website:

To view the original version on PR Newswire, visit:

SOURCE ReportBuyer

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store